Characterisation of the antibody response to the extracellular region of recombinant thyrotropin receptor.
Autoantibodies to the human thyrotropin receptor (TSH-R) are pathogenic in a number of autoimmune thyroid diseases including Graves' disease. We have characterised polyclonal antisera to TSH-R for antibodies which may mimic those present in autoimmune thyroid disease. For immunisations, recombinant extracellular region of human TSH-R which does not interact with its ligand TSH was used. The induced antibodies react with the full length membrane receptor in transfected mammalian cells by flow cytometry showing the presence of antibody capable of recognising the native functional receptor. The properties of the generated antibodies have been compared after two injections or following a multiple immunisation protocol with the receptor in adjuvant. High titre antisera were readily generated after the short injection protocol and further immunisations did not lead to any change in antibody titers. Analysis of the epitopes recognised using synthetic peptides confirmed previous observations that the immunodominant determinants localise to the amino and the carboxyl terminal part of the extracellular region of the receptor. Antisera from both rabbits contain TSH blocking antibody as assessed by inhibition of TSH mediated cAMP stimulation. There was an increase in TSH binding inhibitory immunoglobulin (TBII) activity with multiple injections. Furthermore, the increase in TBII activity was not related to spreading of the antibody response to new determinants on TSH-R. Our results support previous observations on the difficulties in reproducing, by adjuvant immunisation with recombinant TSH-R preparations, the fine specificity of antibodies to TSH-R present in autoimmune disorders such as Graves' disease or primary myxoedema.
Morgenthaler
N G
NG
Department of Medicine, King's College School of Medicine, London, UK.
Kim
M R
MR
Gardas
A
A
Vlase
H
H
Aust
G
G
Gupta
M
M
McGregor
A M
AM
Banga
J P
JP
D000818:Animals; D019138:Antibodies, Blocking / Q000096:biosynthesis* / Q000097:blood / Q000502:physiology; D017151:Antibodies, Catalytic / Q000032:analysis; D015153:Blotting, Western; D002478:Cells, Cultured; D002846:Chromatography, Affinity; D006224:Cricetinae; D000242:Cyclic AMP / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping; D005434:Flow Cytometry; D006111:Graves Disease / Q000276:immunology; D006801:Humans; D007106:Immune Sera / Q000276:immunology / Q000502:physiology; D007114:Immunization; D018828:Immunoglobulins, Thyroid-Stimulating / Q000096:biosynthesis* / Q000097:blood / Q000502:physiology; D007313:Insecta; D009230:Myxedema / Q000276:immunology; D011233:Precipitin Tests; D011817:Rabbits; D011863:Radioimmunoassay; D011989:Receptors, Thyrotropin / Q000096:biosynthesis / Q000276:immunology* / Q000502:physiology; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology; D013972:Thyrotropin / Q000276:immunology / Q000502:physiology; D014162:Transfection
D019138:Antibodies, Blocking; D017151:Antibodies, Catalytic; D007106:Immune Sera; D018828:Immunoglobulins, Thyroid-Stimulating; D011989:Receptors, Thyrotropin; D011994:Recombinant Proteins; D013972:Thyrotropin; D000242:Cyclic AMP